Last reviewed · How we verify
New Formulation Etanercept
New Formulation Etanercept blocks the action of tumor necrosis factor-alpha (TNF-α), reducing inflammation.
New Formulation Etanercept blocks the action of tumor necrosis factor-alpha (TNF-α), reducing inflammation. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.
At a glance
| Generic name | New Formulation Etanercept |
|---|---|
| Sponsor | Amgen |
| Drug class | TNF inhibitor |
| Target | TNF-α |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Etanercept binds to TNF-α, preventing it from interacting with its receptors on the surface of cells, thereby inhibiting the inflammatory response that contributes to various autoimmune diseases.
Approved indications
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Plaque psoriasis
Common side effects
- Infections (e.g., upper respiratory infections, sinusitis)
- Injection site reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |